Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionHumanized autologous T cells loaded with a lentiviral vector expressing CART-19, which consists of a cancer antigen-binding domain targeting CD19 linked to CD3zeta/CD137 immunostimulatory domains
Molecular Target CD19
Mechanism of Action 
Therapeutic ModalityCell therapy
Latest Stage of DevelopmentPhase I
Standard IndicationChronic lymphocytic leukemia (CLL)
Indication DetailsTreat relapsed or refractory CD19-positive leukemia and lymphoma
Regulatory Designation
PartnerUniversity of Pennsylvania

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today